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Summary
To assess the accuracy of increased troponin (Tn) concentrations for the prediction of mid-term (12 months) mortality after coronary artery
bypass graft (CABG) and valve surgery, we performed a systematic review identifying all studies reporting on the association between
postoperative troponin release and mortality after cardiac surgery. Studies were identified through 30 April 2008 by electronic searches of
the MEDLINE, EMBASE and BIOSIS databases. Two reviewers independently selected studies, assessed methodological quality and extracted the
data. We primarily considered mid-term (12 months) and secondarily short-term (30 days) all-cause mortality. A bivariate random-effects
model was used to study determinants and to pool measures of prognostic accuracy of Tn. Seventeen studies fulfilled the inclusion criteria with a
total of 237 mid-term deaths in 5189 patients and 296 short-term deaths in 9703 patients. The diagnostic odds ratio of increased Tn
concentrations was 5.46 (95% confidence interval (CI) 2.0—14.6) for mid-term mortality and 6.57 (95% CI 4.3—10.1) for short-term mortality
after adult cardiac surgery. Alternatively expressed, for troponin elevation, the sensitivity was 0.45 (0.26—0.67) and the specificity 0.87 (0.73—
0.90) to predict mid-termmortality. The sensitivity was 0.59 (0.48—0.69) and the specificity 0.82 (0.72—0.89) for short-termmortality. Between-
study variability was high. In conclusion, this meta-analysis provides evidence for an association between postoperative Tn release with mid- and
short-term all-cause mortality after adult cardiac surgery. However, differences in populations, timing of Tn testing, Tn subunit and Tn assays
make definitive conclusions about effect size and cut-off values difficult.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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The increasing interest in provider profiling and optimisa-
tion of health-care resources in cardiac surgery has been
accompanied by the development of numerous risk-stratifi-
cation models [1], which consider pre- and intra-operative
risk predictors exclusively. Postoperatively, however, the
estimation of prognosis cannot be based solely on risk-
stratification tools developed for preoperative risk stratifica-
tion and provider profiling. Perioperative events have a
recognised association with morbidity [2—6] and mortality
[7,8] but would, therefore, end up being disregarded.
To extend the prognosis to the postoperative condition,
several studies addressed the impact of troponin release on
outcome after adult cardiac surgery.
We conducted a systematic review to clarify the
prognostic value of postoperatively increased troponin levels* Corresponding author. Tel.: +41 61 328 6469; fax: +41 61 265 7320.
E-mail address: luratig@uhbs.ch (G.A. Lurati Buse).
1010-7940/$ — see front matter # 2009 European Association for Cardio-Thoracic
doi:10.1016/j.ejcts.2009.05.054for the prediction of mid-term (12 months) and short-term
(30 days) all-cause mortality in adults undergoing coronary
artery bypass graft (CABG) and valve surgery.
2. Methods
2.1. Study identification
Studies reporting on the association between troponin
release and all-cause mortality in adult undergoing
CABG and valve surgery were identified through 30 April
2008 by electronic searches of the MEDLINE, EMBASE and
BIOSIS databases. All electronic searches were performed
without language restriction and were completed by
manual searches of the reference list of each article. A
search strategy (Appendix 1) based on the terms troponin
and cardiac surgical procedures, and validated combina-
tions of prognostic [9,10] and diagnostic terms [11,12] was
used.Surgery. Published by Elsevier B.V. All rights reserved.
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troponin levels as the endpoint and lacking information
about all-cause mortality and cardiac morbidity were
excluded, as were reports lacking specific information
about patients’ number, inclusion/exclusion criteria, event
definition, follow-up duration or patient demographics. To
avoid considering repeatedly published data, we excluded
articles presenting preliminary results if a later article was
available.
Study selection was performed independently by two
readers (GLB and MG). Inconsistencies were resolved by
consensus.
2.2. Descriptive data
Descriptive data of the studies including the study sample
size, planned follow-up duration and completeness of follow-
up, surgical procedures, median age, gender proportion,
elective versus urgent/emergency proportion, acute cor-
onary syndrome (ACS) proportion and definition, troponin
cut-off level and timing of blood sample collection were
registered. For descriptive purposes, we recorded multi-
variate adjusted odds ratio (OR) or hazard ratio (HR)
estimates, if available, together with the adjustment
variables used to derive the troponin effect.
2.3. Outcome data
Data were primarily extracted for mid-term (12 months)
all-cause mortality. Studies reporting on all-cause mortality
for short-term (30 days) or in-hospital periods only were
considered secondarily. In addition, the occurrence of major
non-fatal adverse cardiac events (MACE) for mid- and short-
term was assessed. The latter consisted of myocardial
infarction, congestive heart failure and low output syndrome
as defined in the respective studies. The number of events
was extracted according to troponin levels above and below
the given cut-off level to calculate true and false positive and
negative rates, respectively, as needed for statistic analysis.
Missing information was sought by written correspondence
with the authors. One paper [13] reported the study results
per unit troponin increase (per 10-mg l1 increase in TnI
concentration). In this case, we used the 75th-percentile
troponin level (8.49 mg l1) reported in the paper [13] as the
cut-off value.
Mid- and short-term all-causemortality were statistically
analysed. Due to widely diverging definitions of MACE,
results for MACE were summarised in a descriptive manner
only.
2.4. Study quality assessment
The quality of the methodology of the included studies
was evaluated according to the QUADAS-checklist [14]. The
questions of the checklist were modified to fit the prognostic
setting of our review. Therefore, the terms index test, target
condition and reference standard appearing in the QUADAS-
checklist were replaced with troponin concentration mea-
surement, mortality, and follow-up/outcome assessment in
the modified checklist, respectively. The details of the
modified checklist are reported in Appendix 2.2.5. Statistical analysis
Frequencies are described as number and/or percent and
agreement between the readers for inclusion of the retrieved
studies as k-value.
A bivariate random-effectsmeta-regressionmodel [15]was
used toobtain summaryestimates of sensitivityand specificity.
The bivariate model preserves the two-dimensional nature of
the data through the joint analysis of the pairs of the logarithm
transformed (logit) sensitivity {log[sens/(1  sens)]} and
specificity {log[spec/(1  spec)]} of each study in the
mixed-model framework. By using the random-effects
approach, the model assumes between-study heterogeneity
as a consequence of chance variability, differences in study
populations and studydesignof the included studies andallows
for it. This bivariate model, thus, calculates a random-effect
estimate of the mean sensitivity and specificity together with
their 95%confidence intervals (CIs). After back-transformation
of the estimates (antilogit) to the probability scale, pooled
estimates are plottedwithin the ROC space and, togetherwith
the correlation between the sensitivity and specificity, a 95%
confidence area around the summary estimate of sensitivity
and specificity can be produced. The 95% confidence area can
be viewed as a two-dimensional confidence interval. Themain
axis of the 95% confidence area reflects the correlation
between sensitivity and specificity (threshold effect). In
addition to the 95% confidence area, the bivariate models
allows for the calculation of a 95% prediction area, which can
be viewed as the two-dimensional standard deviation of the
individual studies. The area of 95% prediction area that
reaches beyond the 95% confidence area reflects significant
between-study variation.
Covariates can be introduced into the bivariate model to
explain between-study variation of sensitivity and specificity.
In this study, we predefined the type of surgery (studies of
CABG only vs CAGB and/or valvular surgery) as the only
explanatory covariate in our model. Moreover, we performed
sensitivity analyses restricting meta-analyses to studies that
reported a total of at least 10 deaths.
A standard correction of 0.5 was applied to those cells of
the 2  2 contingency tables without events. The bivariate
model was fitted in SAS version 9.1 for Windows (SAS
Institute, Cary, NC, USA).
3. Results
3.1. Description of studies
Seventeen of the 1215 citations identified fulfilled the
inclusion criteria (Fig. 1). The chance-corrected k-value for
agreement on study inclusion was 0.7 (crude agreement was
1205/1215 or 0.99).
Two studies reported on mid-term (12 months) results
[16,17], eight on short-term (30 days) results [18—25] and
seven on both [13,26—31], with a total of 237 mid-term
deaths by any cause in 5119 patients and 296 short-term
deaths by any cause in 9703 patients. Six of the mid-term
studies [17,26—28,30,31] described the completeness of
their follow-up that ranged from 84% to 100%. Table 1 reports
the details of the studies included.
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Fig. 1. Selection process of the identified citations.
Fig. 3. OR and summary dOR for the association between troponin release and
short-term mortality after cardiac surgery.Two studies [16,20] only showed adjusted associations of
troponin with all-cause mortality and crude data could not be
obtained. Therefore, these studies could not be used for
statistical pooling and were only reported descriptively
(Table 2). The adjusted results of both these studies and of
the remaining studies presenting adjusted estimates
[13,17,22,28] are summarised as published in the respective
papers (Table 2). The positive and negative predictive values
for all-cause mortality in the single studies are described in
Tables 3 and 4, as a meta-analytic method to obtain summary
estimates for those values is not available.
3.2. Accuracy of troponin release for the prognosis of all-
cause mortality
3.2.1. Summary estimates
The summary estimates of the association (dOR [95%
confidence intervals]) of troponin above versus below the
cut-off in an individual study and the occurrence of death
after adult cardiac surgery was 5.46 (95% CI: 2.0—14.6) for
mid-term all-cause mortality and 6.57 (95% CI: 4.3—10.1) for
short-term all-cause mortality (Figs. 2 and 3).
Alternatively expressed, troponin elevation had an
average sensitivity of 0.45 (0.26—0.67) and a specificity of
0.87 (0.73—0.90) for the prediction of mid-term all-causeFig. 2. OR and summary dOR for the association between troponin release and
mid-term mortality after cardiac surgery.mortality. For the prediction of short-term all-cause
mortality, elevated troponin reached an average sensitivity
of 0.59 (0.48—0.69) and a specificity of 0.82 (0.72—0.89).
The bivariate 95% confidence area in the ROC plane around
the pooled mean values [32] of sensitivity and specificity are
depicted in Fig. 4a and b.Fig. 4. (a) Summary estimate and 95% confidence area of the sensitivity and
specificity of troponin release for mid-termmortality. The 95% prediction area is
a measure for between-study variability. (b) Summary estimate and 95% con-
fidence area of the sensitivity and specificity of troponin release for short-term
mortality. The 95% prediction area is a measure for between-study variability.
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2Table 1
Characteristics of the included studies.
Study Design Sample
size
Events
(%)
Endpoint Follow-up CABG
(%)
Elective
surgery (%)
Male
(%)
Age
(years)
Tn
unit
Cut-off
(mg l1)
Increased
Tn levels
Sample
collection
time
Nesher et al. (2008) 1 Prospective cohort of consecutive patients 1515 21 (0.01) All-cause mortality Inhospital 100 62 82 65 TnTa 0.8 40.6% Peak value
Sellgren et al. (2007) Retrospective cohort of consecutive patients 2751 119 (9.7) All-cause mortality 30 days/
24 months
72.0 100 74 66 TnTb 2.0 3.7% 96 h
Riedel et al. (2006) Prospective cohort of consecutive patients 70 20 (8.7) MACE 36 months 100.0 100 92.8 60.2 TnIc 15.0 32.8% Peak value
Croal et al. (2006) Prospective cohort of consecutive patients 1356 65 (4.8) All-cause mortality 30 days/
12 months
76.7 100 75.0 66.2 TnId Continuous
values
2 and 24 h
Provenche`re et al. (2006) Prospective cohort of consecutive patients 92 9 (9.8) All-cause mortality Inhospital/
12 months
46.7 100 66.3 66.0 TnIe 13.0 2.2% 24 h
Paparella et al. (2005) Cohort of consecutive patients 230 20 (8.7) All-cause mortality Inhospital/
24 months
100.0 NS 78.7 65.1 TnI f 13.0 36.5% Peak value
Kathiresan et al. (2004) Prospective cohort of consecutive patients 136 7 (5.2) All-cause mortality 12 months 100.0 NS 77.0 67.0 TnTg 1.58 20.0% 18—24 h
Lehrke et al. (2004) Prospective cohort of consecutive patients 204 11 (5.4) All-cause mortality Inhospital/
24 months
64.7 100 64.7 63.3 TnTa 0.46 6.9% 48 h
Fellahi et al. (2003) Prospective cohort of consecutive patients 202 9 (4.4) All-cause mortality Inhospital/
24 months
100.0 100 90.6 64.0 TnIh 13.0 2.5% 24 h
Leal et al. (2003) Cohort of random patients 88 5 (5.6) All-cause mortality Inhospital/
12 months
100.0 NS 73.9 NS TnI i 2.5 2.3% 24 h
Berendes et al. (2003) Prospective cohort of consecutive patients 60 10 (16.7) All-cause mortality 24 months 100.0 100 80.0 64.0 TnI j Not applicable 12 h
Fellahi et al. (2007) 2 Prospective cohort of consecutive patients 431 121 (28.1) All-cause mortality
and MACE
Inhospital 0.0 100 64 73 TnIh 9.33, 11.84 41.3% 24 h
Adabag et al. (2007) Cohort of consecutive patients 1186 51 (4.3) 30-day mortality 30 days 58.7 92.7 99.0 66.0 TnI h Continuous
values
24 h
Cosgrave et al. (2006) Prospective cohort of consecutive patients 100 2 (2) 30-day mortality 30 days 100.0 100 83.0 62.0 TnTk 1 5.0% 24 h
Fellahi et al. (2004) Randomized controlled study without
difference in the groups
359 6 (1.6) All-cause mortality Inhospital 60.7 100 72.4 67.0 TnI h 13 20.6% 24 h
Lasocki et al. (2002) Prospective cohort of consecutive patients 502 28 (5.6) All-cause mortality Inhospital 37.0 93 86.8 63.0 TnI l 13.0 11.0% 20 h
Eigel et al. (2001) Prospective cohort of consecutive patients 540 21 (3.9) All-cause mortality,
MACE
Inhospital 100.0 100 69.0 68.7 TnIm 0.495 NS End of CPB
Ponce et al. (2001) Cohort of consecutive patients 147 14 (9.5) All-cause mortality Inhospital 0.0 100 54.4 59.1 TnI n 38.85 16.0% 14 h
CABG: coronary artery bypass graft; NS: not stated; MACE: major adverse cardiac events; CPB: cardiopulmonary bypass.
a Elecsys 2010, Roche Diagnostics.
b Kit not stated.
c Opus kit, Dade-Behring.
d ADVIA, Bayer Diagnostics.
e RXL HM, Dade-Behring.
f Not fully stated, Dade Behring.
g Elecsys 1010, Roche Diagnostics.
h AxSYM, Abbot Laboratories.
i Acess, Sanofi-Pasteur.
j Dimention RxL, Dade-Behring.
k Cardiac T Diagnositc Reader, Roche Diagnostics.
l Stratus II, Dade-Behring.
m Stratus CS, Dade-Behring.
n Stratus, Dade-Behring.
1 Only CABG patients included (all-cause mortality data was available for these patients only).
2 Non-CABG patients included.
3 Cut-off value for valve surgery.
4 Cut-off value for combined surgery.
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Table 2
Multivariate association of troponin increase with stated endpoints of the included studies.
Study Events Tn Endpoint Multivariate adjusted
association
Adjustment variables
Croal et al. (2006) n = 65 I 12-month
mortality
OR 1.1 (1.03—1.2)
per 10 mg l1
Age, gender, BMI, smoking status, hypertension, diabetes,
hypercholesterolaemia, inotrope requirement, EuroSCORE, cross-clamp time,
previous myocardial infarction, NYHA functional class, left main stem
stenosis >50%, EF <50%, preoperative creatinine, estimated GFR, complex
surgery, postoperative ventricular dysrythmia, postoperative septicemia
Kathiresan et al.
(2004)
n = 7 T 12-month
mortality
OR 5.4 (4.5—232.5) Age, gender, presenting syndrome, cardiovascular risk factors, medication,
CAD’s extent, EF, repeat CABG, type of cardioplegia, surgical procedures
Lehrke et al.
(2004)
n = 11 T 24-month
mortality
OR 4.9 (1.02—23.9) Gender, type of surgery, preoperative TnT levels, cross clamp-time,
cardiovascular risk factors
Berendes et al.
(2004)
n = 10 I 24-month
mortality
HR 1.0 (0.83—1.2) Preoperative BNP, duration of intraoperative myocardial ischaemia,
Cleveland score, preoperative left ventricular ejection fraction,
postoperative wall motion abnormalities
Nesher et al. (2008) n = 255 T Inhospital
mortality and MACE
OR 2.7 (2.08—3.5) Age >70 years, gender, EF <40%, CPB time, NYHA functional class,
preoperative cerebrovascular accident
Lasocki et al. (2002) n = 28 I Inhospital
mortality
OR 6.7 (2.3—19.3) Age, gender, diabetes, altered LV function, emergent surgery, NYHA
functional class, surgery type, CPB time, chest drainage volume,
postoperative arterious pO2
Eigel et al. (2001) n = 21 I Inhospital
mortality and MACE
OR 17 (5.5—54) Age, gender, diabetes EF <40%, Cleveland clinic preoperative severity score,
ross clamp time, CPB time, preoperative creatine level, number of grafts
BMI: body mass index; NYHA: New York Heart Association; EF: ejection fraction; GFR glomerular filtration rate; LV: left ventricular; CPB: cardiopulmonary bypass.3.2.2. Between-study variability and sensitivity analysis
For sensitivity, the 95%prediction interval ranged from0.09
to 0.88 and from 0.31 to 0.82 formid- and short-termall-cause
mortality, respectively. For specificity, the 95% prediction
interval ranged from0.44 to0.98and from0.38 to0.97 formid-
and short-term all-cause mortality, respectively. Therefore,Table 4
Positive and negative predictive values of the single studies for short-term all-
cause mortality.
Study Positive
predictive value
Negative
predictive value
Nesher et al. (2008) 0.03 0.99
Fellahi et al. (2007) 0.47 0.85
Sellgren et al. (2007) 0.09 0.99
Adabag et al. (2007) 0.09 0.97
Croal et al. (2006) 0.05 0.99
Cosgrave et al. (2006) 0.12 0.98
Paparella et al. (2005) 0.10 0.99
Lehrke et al. (2004) 0.06 1.00
Fellahi et al. (2004) 0.01 0.98
Fellahi et al. (2003) 0.11 0.99
Lasocki et al. (2002) 0.28 0.97
Ponce et al. (2001) 0.50 0.98
Table 3
Positive and negative predictive values of the single studies for mid-term all-
cause mortality.
Study Positive
predictive value
Negative
predictive value
Sellgren et al. (2007) 0.15 0.96
Croal et al. (2006) 0.10 0.96
Provenchere et al. (2006) 0.10 0.90
Paparella et al. (2005) 0.10 0.90
Kathiresan et al. (2004) 0.22 0.99
Lehrke et al. (2004) 0.50 0.98
Fellahi et al. (2003) 0.19 0.97
Leal et al. (2003) 0.33 0.97the data showed large between-study variability as reflected
by the large area of the 95% prediction area beyond the 95%
confidence area (Fig. 4a and b).
To address between-study variability, we initially assessed
threshold effect, a frequent source of variability between
diagnostic studies. Threshold effect was not present in the
mid-term results (correlation coefficient between logit
(sensitivity) and logit (specificity) 0.07, p = 0.9). In contrast,
threshold analysis resulted in a significant threshold effect
for short-term data (correlation coefficient between logit
(sensitivity) and logit (specificity) 0.64, p = 0.024).
Subsequently, we determined whether the results from
CABG surgery populations versus mixed CAGB and/or valvular
surgery populations differed. The variable dOR ( p = 0.80 for
mid-term and p = 0.88 for short-term all-cause mortality),
sensitivity ( p = 0.60 for mid- and p = 0.77 for short-term all-
cause mortality) and specificity ( p = 0.80 for mid-term and
p = 0.90 for short-term all-cause mortality) were not
significantly influenced by the type of cardiac surgery.
Finally, we performed sensitivity analyses by restricting the
pooled analyses to studies reporting at least 10 deaths. The
dOR in studieswithmore than 10 deathswas 4.65 (0.98—22.16)
and 6.63 (3.83—11.47) for mid- and short-term all-cause
mortality, respectively. Themean sensitivity in the studieswith
more than 10 deaths was 0.43 (0.16—0.75) and 0.58 (0.46—
0.69) for mid- and short-term, respectively. The specificity in
the same studies was 0.86 (0.63—96) and 0.83 (0.68—0.91) for
mid- and short-term all-cause mortality, respectively.
3.3. Quality assessment
All of the included studies fulfilled the requirements of a
representative spectrum of patients, of outcome verifica-
tion in the whole cohort, of equal outcome evaluation,
regardless of the troponin results and of availability of
clinical data. We considered the description of the troponin
measurement (index test) sufficient for replication in 15
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31] of 17 studies clearly described their criteria for selecting
patients. Of the 12 studies that did not address in-hospital
all-cause mortality, only eight described the follow-up
methods (execution of the reference standard) used
[13,17,26,28—30]. Only two studies [18,19] stated that
outcomewas interpretedwithout knowledge of the troponin
results. Six of the 17 studies described the reasons for
withdrawal [18,22] or loss of follow-up [26,28,30].
4. Discussion
4.1. Clinical interpretation
The data summarised in this meta-analysis showed a clear
association between troponin release after cardiac surgery
and mid- and short-term all-cause mortality. The evidence of
the prognostic impact of troponin release after adult cardiac
surgery is supported by a concentration—response effect
reported in a study by Croal et al. [13] for mid-term all-cause
mortality and in studies by Adabag et al. [18] and by Nesher
et al. [25] for the short-term all-cause mortality.
A similar association between troponin release and
outcome has previously been shown primarily in non-surgical
populations, for example, in patients presenting with ACSs
[33—36], in patients undergoing percutaneous coronary
intervention (PCI) for stable angina or ACS [37], and in
critically ill patients [38]. In addition, an association between
troponin release and outcome was shown for patients
undergoing major non-cardiac surgery [39—44].
The strength of association between troponin release and
outcome in these conditions was comparable to the
association found in patients after cardiac surgery reported
here. One study in patients with ACS reported an OR of 3.1
(95% CI: 2.3—4.1) for 30-day [36] mortality and an OR of 1.93
(95% CI: 1.46—2.53) for 1-year mortality. After non-cardiac
surgery, the association between elevated troponin and all-
cause mortality ranged from 10.2 (2.8—37) at 12 months [40]
to 2.15 (1.4—3.4) at 32 months [39]. Thus, the association
between loss of myocardial cells (expressed by troponin
release) and mortality lies in a similar range independent of
the initial cause for myocardial damage.
Troponin is not expected to be in the circulation in
patients with no previous heart operation. Accordingly, any
measurable troponin release can be associated with adverse
outcome. This fact is reflected by cut-off values for adverse
outcome near the upper reference limits for the troponin
tests used [33—36,38—48]. In contrast, patients undergoing
cardiac surgery, atriotomy, surgical manipulation, incom-
plete cardioprotection, aortic cross-clamping [49], defibril-
lation and reperfusion damage related to on-pump surgery
are expected to experience a certain and inevitable degree
of troponin release. As expected, cut-off levels found in
studies of patients after cardiac surgery were several times
higher than the upper limit of the test kits [22,24—26,29,30].
Thus, troponin concentrations exceeding a certain level
(caused by some unavoidable surgery-induced troponin
release) indicate more extensive myocardial damage, and
this more severe myocardial damage is associated with
adverse outcome.Increased troponin release after on-pump cardiac surgery
showed higher specificity than sensitivity, provided the cut-
offs applied in the different studies. This suggests a stronger
average ability of a positive troponin test for the prediction
of all-cause mortality than of a negative troponin test to
exclude it. In clinical practice, elevated troponin concentra-
tion after on-pump cardiac surgery represents, therefore, a
sign indicating patients at risk for higher mid- and short-term
all-cause mortality.
Should a benefit in prognostic value by the combination of
troponin and preoperative risk-stratification tools be con-
firmed, then troponin measurements might be of particular
interest to identify the false negative patients of the
preoperative risk-stratification, that is, the patients mis-
classified by preoperative risk stratification as having a good
prognosis.
We analysed the effect of the type of surgery and found no
impact of surgery type on the association between troponin
concentration and mortality. This may be due to the limited
power of the sensitivity analysis resulting from too few
studies. It may also be based on the fact that studies enrolling
CABG patients only were compared to studies addressing any
type of cardiac surgery. However, the latter often included a
large proportion of CABG patients, which diluted the
potential difference in the predictive value of troponin, as
described by Croal et al. [13] in the subgroup of patients
undergoing CABG alone. In this meta-analysis, separate
evaluation of CABG versus valvular surgery patients was not
possible as the data of the subgroup of patients undergoing
valvular surgery was generally not presented.
4.2. Methodological consideration
Following the concept of diagnostic research, the
bivariate model allows a two-dimensional perception of
troponin as a diagnostic test to predict mortality. Thus, we
can appreciate that for both mid- and short-term all-cause
mortality, elevated troponin levels generally showed a higher
specificity (0.73—0.90) than sensitivity (0.26—0.67).
The large number of false-negative results may be related
to non-cardiac death. This point is supported by the lower
number of false-negative classifications during the first
period (in-hospital or 30 days) after cardiac surgery when the
ratio of cardiac versus non-cardiac death is expected to be
higher. An alternative interpretation is that most studies
calibrated their cut-off values in a way that resulted in high
specificity and low sensitivity, as their goal was to detect a
hard outcome (death by any cause) by a single parameter,
rather than excluding its occurrence (as in a screening
situation).
The studies included showed large between-study varia-
bility. Frequent sources of between-study variability in
diagnostic or prognostic accuracy parameters include
different threshold values used to determine individual
study sensitivities and specificities. Such a threshold effect is
reflected by a negative correlation between sensitivity and
specificity of the single studies or by a positive correlation
between sensitivity and specificity in the summary ROC
plane. There was a significant threshold effect in studies
addressing short-term but not mid-term all-cause mortality.
Alternatively expressed, reports yielding high sensitivities
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for short-term all-cause mortality. This may be due to the
choice of cut-off values (with more emphasis on specificity
and less on sensitivity) and endpoint (all-cause mortality, due
to the shift of the cardiac versus non-cardiac cause of
death ratio towards non-cardiac death after an extended
follow-up).
To address the potential effect of a small number of
events, we also restricted our analysis to studies with a total
of at least 10 deaths as a potential source of variability
without detection of any difference. This may be the
consequence of low power of the sensitivity analysis due
to the few articles available.
By the assessment of the study quality, we did not
identify striking differences between the studies. Follow-
up completeness, method to assess outcome and blinding of
study collaborators to troponin concentration were rarely
described. However, all-cause mortality as primary out-
come does not allow for interpretation. Most studies
suffered from a limited sample size. Further, all studies
failed to provide statements on sample size calculation and
its adequacy.
4.3. Limitations
Caution in the appraisal of the pooled results is warranted
in the presence of large between-study variability, even
when considering calculation from random-effect model.
The large between-study variability seems to be based on
characteristics other than those mentioned above. First, the
included studies differed in study population as reflected by
marked differences in mortality, independent of the type of
surgery performed. Second, the studies assessed all-cause
mortality after a variable follow-up period and with different
degrees of completeness. However, potential censoring of
observations was not considered in the bivariate model.
Third, the assays used and the timing of blood sample
collection (0—96 h postoperatively) as well as the measured
troponin subunit differed.
A further limitation is that the presented dORs reflect
unadjusted association between troponin release and all-
cause mortality after cardiac surgery. To what extent
increased troponin values implement the prognostic value
of established preoperative risk stratification cannot be
addressed by the results of this meta-analysis.
We limited the statistical analysis to all-cause mortality. If
data on MACE were published in a study reporting on
mortality, we summarised the results for MACE only
descriptively due to the widely diverse definitions of MACE.
The study by Riedel et al. [50] was excluded as it reported on
MACE only.
It should be emphasised that we focussed on post-
operative troponin readings disregarding the impact pre-
operative readings.
An additional limiting factor is the reduced number of
studies available despite using a sensitive search strategy
without language restriction for three electronic databases
and a manual search of the reference lists of the included
papers (Appendix 1).
Finally, in our hypothesis, we did not pre-specify whether
one dimension (sensitivity or specificity of the bivariatemodel) was expected to dominate the hypothesised prog-
nostic value expressed by dOR.
5. Conclusions
This systematic review and meta-analysis supports the
association between postoperative Tn release and mid- and
short-term all-cause mortality after adult cardiac surgery.
However, differences in the populations, outcome defini-
tions, timing of the Tn testing, Tn subunit and Tn assays make
a definitive conclusion regarding effect size difficult, and
regarding cut-off values impossible.
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